AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter GrowthInvestors Business Daily • 11/10/22
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend StocksThe Motley Fool • 11/10/22
Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022 - AstraZeneca (NASDAQ:AZN)Benzinga • 11/09/22
AstraZeneca shares will get lift from heartburn litigation closure, says CitiProactive Investors • 11/01/22
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer ResearchPRNewsWire • 10/27/22
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast CancerBusiness Wire • 10/26/22
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancerBusiness Wire • 10/26/22